REVIEW ARTICLE

WILEY   BIPOLAR DISORDERS
AN INTERNATIONAL JOURNAL OF PSYCHIATRY AND NEUROSCIENCES

Systematic assessment of environmental risk factors for bipolar disorder: an umbrella review of systematic reviews and meta-analyses

Beatrice Bortolato[1] | Cristiano A. Köhler[2] | Evangelos Evangelou[3,4] | Jordi León-Caballero[5,6] | Marco Solmi[1,7,8,9] | Brendon Stubbs[10,11,12] | Lazaros Belbasis[3] | Isabella Pacchiarotti[5] | Lars V. Kessing[13] (iD) | Michael Berk[14,15,16] | Eduard Vieta[5] | André F. Carvalho[1,2] (iD)

[1]Institute for clinical Research and Education in Medicine, I.R.E.M., Padova, Italy

[2]Department of Clinical Medicine and Translational Psychiatry Research Group, Faculty of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil

[3]Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece

[4]Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK

[5]Bipolar Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain

[6]Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, CIBERSAM, Universidad Autonoma de Barcelona, Barcelona, Catalonia, Spain

[7]Department of Neurosciences, University of Padova, Padova, Italy

[8]Local Health Unit 17 ULSS 17, Mental Health Department, Padova, Italy

[9]Department of Medicine, DIMED, Geriatrics Division, University of Padova, Padova, Italy

[10]Physiotherapy Department, South London and Maudsley NHS Foundation Trust, London, UK

[11]Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

[12]Faculty of Health, Social care and Education, Anglia Ruskin University, Chelmsford, UK

[13]Psychiatric Centre Copenhagen, Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

[14]IMPACT Strategic Research Centre (Barwon Health), School of Medicine, Deakin University, Geelong, VIC, Australia

[15]Florey Institute for Neuroscience and Mental Health, Department of Psychiatry, University of Melbourne, Melbourne, Australia

[16]Orygen, The National Centre of Excellence in Youth Mental Health, University of Melbourne, Melbourne, Australia

Correspondence
André F. Carvalho, Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Emails: andrefc7@terra.com.br; andrefc7@hotmail.com

Objectives: The pathophysiology of bipolar disorder is likely to involve both genetic and environmental risk factors. In our study, we aimed to perform a systematic search of environmental risk factors for BD. In addition, we assessed possible hints of bias in this literature, and identified risk factors supported by high epidemiological credibility.

Methods: We searched the Pubmed/MEDLINE, EMBASE and PsycInfo databases up to 7 October 2016 to identify systematic reviews and meta-analyses of observational studies that assessed associations between putative environmental risk factors and BD. For each meta-analysis, we estimated its summary effect size by means of both random- and fixed-effects models, 95% confidence intervals (CIs), the 95% prediction interval, and heterogeneity. Evidence of small-study effects and excess of significance bias was also assessed.

Results: Sixteen publications met the inclusion criteria (seven meta-analyses and nine qualitative systematic reviews). Fifty-one unique environmental risk factors for BD were evaluated. Six meta-analyses investigated associations with a risk factor for BD. Only irritable bowel syndrome (IBS) emerged as a risk factor for BD supported by convincing evidence (k=6; odds ratio [OR]=2.48; 95% CI=2.35–2.61; P<.001), and childhood adversity was supported by highly suggestive evidence. Asthma and obesity were risk factors for BD supported by suggestive evidence, and seropositivity to *Toxoplasma gondii* and a history of head injury were supported by weak evidence.

Conclusions: Notwithstanding that several environmental risk factors for BD were identified, few meta-analyses of observational studies were available. Therefore, further well-designed and adequately powered studies are necessary to map the environmental risk factors for BD.

KEYWORDS

aetiology, bipolar disorder, depression, mania, meta-analysis, mood disorder, psychiatry, risk factor, systematic review

1 | INTRODUCTION

Bipolar disorder (BD) has an estimated lifetime prevalence of 0.6% for type I BD, 0.4% for type II BD, and 1.4% for subthreshold BD across 11 countries.[1] Bipolar disorder is also associated with substantial morbidity and mortality due to a high prevalence of co-occurring medical (e.g., metabolic) and psychiatric conditions, as well as elevated suicide rates.[2–5] Evidence indicates that BD is largely influenced by genetic factors, with an estimated heritability of 58%–85%.[6,7] However, genome-wide association studies indicate that the cumulative impact of many common alleles of small effect may explain only 38% of the phenotypic variance for BD.[8] Furthermore, emerging evidence indicates that complex gene−environment interactions including epigenetic mechanisms may play a significant role in the patho-aetiology of BD.[9,10]

Therefore, the identification of putative modifiable risk factors for BD may ultimately aid in the prevention of this devastating illness. Furthermore, emerging evidence suggests that neurodevelopmental pathways may be involved in the aetiopathogenesis of a subset of individuals with BD.[11-13] These data indicate that perinatal and early-life insults may contribute to the pathophysiology of BD. Accordingly, previous systematic reviews indicate that perinatal infections (e.g., influenza and *Toxoplasma gondii* infection) may confer a higher risk of BD.[14,15] In addition, exposure to childhood maltreatment is thought to increase the risk of BD, and also may have a detrimental impact on several BD-related outcomes.[16,17] Finally, a previous systematic review indicates that environmental risk factors occurring later in life (e.g., substance abuse) may also be involved in the development of BD.[16]

To further expand the identification of environmental risk factors for BD, in the current work we aimed to conduct an umbrella review of systematic reviews and meta-analyses of environmental risk factors for BD. Similar reviews have been successfully conducted for a range of neuropsychiatric diseases (e.g., Parkinson's disease and dementia).[18,19] We followed a similar methodology herein, to enable the assessment of hints of bias in this literature, and also the identification of environmental risk factors supported by more credible epidemiological evidence.

2 | MATERIALS AND METHODS

2.1 | Search strategy and study selection

We systematically searched the PubMed/MEDLINE, EMBASE and PsycINFO databases from inception to 7 October 2016 to identify systematic reviews and meta-analyses of observational studies examining associations of environmental (non-genetic) risk factors with BD. The search strategy used the keywords "bipolar disorder" and "meta-analyses or systematic reviews" applied to the title/abstract/keywords fields. Two authors (B.B. and J.L.C.) independently screened the titles/abstracts of retrieved publications, and discrepancies were resolved through consensus. If a final decision could not be reached, a third investigator made the decision regarding possible eligibility (A.F.C. or C.A.K.). The full texts of publications selected after title/abstract screening were then reviewed by the same investigators to determine final eligibility. We included systematic reviews and meta-analyses of observational studies (i.e., cross-sectional, case−control and cohort studies) which investigated environmental risk factors for BD. No language restrictions were applied. Systematic reviews and meta-analyses of genetic risk factors, peripheral biomarkers of BD, factors related to recurrence/relapse of BD or intervention studies were excluded. A published umbrella review evaluated possible hints of bias in the literature of peripheral biomarkers for BD.[20] We also included systematic reviews and meta-analyses in which a disease state was investigated as a putative risk factor for BD (except unipolar depression), but we excluded those where BD was studied as a

risk factor for another disease. In addition, we excluded systematic reviews and meta-analyses that examined personality constructs and prodromal manifestations as putative risk factors for BD. For meta-analyses available only as meeting abstracts, we electronically contacted the authors on at least two separate occasions to provide data. This search strategy was augmented through tracking the citations of included articles in Google Scholar.[21] We followed an a priori defined but unpublished protocol.

2.2 | Data extraction

Two independent investigators (B.B. and J.L.C.) extracted the following information from each included article: (i) first author name; (ii) year of publication; (iii) the examined risk factors; (iv) number of included studies. If a quantitative synthesis of the evidence was performed, we extracted the summary effect size (ES) estimate (risk ratio [RR], odds ratio [OR], hazard ratio [HR], or incident risk ratio) with the 95% confidence intervals (CIs). Whenever available, we also extracted the individual ES estimate and the sample sizes of individual studies. If a study had several control groups, we prioritized the extraction of the association with a healthy control group. In the articles where a summary synthesis of the evidence was not available, we extracted the main conclusions reached by the authors and the reasons for not performing a meta-analysis. Whenever two publications were available for the same risk factor, we considered the one with the largest number of datasets.

2.3 | Statistical analysis

For each meta-analysis, we estimated the summary ES and its 95% CI through both fixed- and random-effects models.[22] For meta-analyses where individual study data were not available, we considered the summary associations published by the authors. We also calculated the prediction interval and its 95% CI, which accounts for between-study heterogeneity and estimates the uncertainty of the association that would be expected in a new study examining that same association.[23] For the largest dataset of each meta-analysis, we calculated the standard error (SE) of the ES. If the SE is <0.1 then the 95% CI will be <0.20 (i.e., less than the magnitude of a small ES). We calculated the I^2 metric to assess between-study heterogeneity. Values ≥50% indicate high heterogeneity and values ≥75% suggest very high heterogeneity.[24,25] To assess evidence for small-study effects (i.e., whether small studies would have inflated ESs compared to larger ones), we used the regression asymmetry test developed by Egger and coworkers.[26] A P value <.10 in Egger et al.'s test and the ES of the largest study being more conservative than the summary ES of the random-effects meta-analysis were considered as indicative of small-study effects.[27] Finally, we assessed whether an excess of significant findings was present by means of Ioannidis's test.[28] In brief, this test evaluates whether the number of studies with nominally significant results (i.e. with P<.05) among those included in a meta-analysis is too large considering their power to detect significant effects at α=0.05. First, we estimate the power of each individual study, using

a non-central t distribution. The sum of all power estimates provides the expected (E) number of datasets with nominal statistical significance. The actual observed (O) number of statistically significant datasets is then compared to the E number using a χ^2-based test.[28] The larger the difference between O and E, the higher the degree of excess of significance bias. Since the true ES of a meta-analysis cannot be precisely determined, we considered the ES of the largest dataset as the plausible true ES. This decision was based on the fact that simulations indicate that the most appropriate assumption is the ES of the largest dataset included in the meta-analysis.[29] Excess significance for a single meta-analysis was considered if P<.10 in Ioannidis's test and O>E.

2.4 | Classification of the credibility of evidence

The epidemiological credibility of the association of each environmental risk factor with BD was classified using criteria derived from previously published umbrella reviews.[18,30] We considered the following criteria: (i) convincing evidence (class I): >1000 cases, significant summary associations ($P<10^{-6}$) per random-effects calculation, no evidence of small-study effects, no evidence of excess of significance bias, prediction intervals not including the null and heterogeneity not large ($I^2<50\%$); (ii) highly suggestive evidence (class II): significant summary associations ($P<10^{-6}$) per random-effects calculation, >1000 cases, and the largest study with 95% CI excluding the null; (iii) suggestive evidence (class III): >1000 cases and significant summary associations ($P<10^{-3}$) per random-effects calculation; (iv) weak evidence: all other risk factors with P<.05; (v) non-significant associations: all associations with P>.05. For risk factors classified as class I or II evidence, sensitivity analyses were performed limiting the evidence only to prospective studies.

2.5 | Methodological quality assessment

Two authors (C.A.K. and A.F.C.) rated the methodological quality of included systematic reviews and meta-analyses with The Assessment of Multiple Systematic Reviews (AMSTAR) instrument.[31] Scores range from 0 to 11, with higher scores indicating greater quality. The AMSTAR scale involves dichotomous scoring (i.e., 0 or 1) of 11 items related to the methodological rigor of systematic reviews and meta-analyses (e.g., comprehensive search strategy and publication bias assessment). AMSTAR scores are graded as high (8–11), medium (4–7) and low quality (0–3).[31,32]

3 | RESULTS

Our search strategy identified 2327 hits, and following exclusion of duplicates and searching other sources, the titles/abstracts of 1205 unique publications were screened for eligibility. Of 65 publications selected for full-text review, 16 met the inclusion criteria. One study of the 65 articles selected for full-text review was excluded because a more recent publication had re-analysed the data.[33,34] Seven of the

FIGURE 1 Flow chart of the literature search [Colour figure can be viewed at wileyonlinelibrary.com]

16 eligible articles had a quantitative synthesis providing a summary estimate of the association of the risk factor and BD.[15,35-40] Individual study data were available for six publications.[15,36-40] Three articles reported prevalence rates of BD in medical conditions, namely endometriosis,[41] fibromyalgia[34] and multiple sclerosis.[42] The remaining seven publications reported only systematic reviews.[14,16,41,43-46] Figure 1 presents a flow chart of study selection, and the reasons for exclusion are summarized in Supporting Information Table S1 (accompanying the online version of this article). The eligible publications evaluated 51 unique risk factors for BD. Seven putative environmental risk factors were assessed in more than one publication. In these cases, we selected the publication that included the highest number of datasets (see Table S2).

Meta-analyses provided evidence for seven environmental factors, and included 54 studies in total (median=8; interquartile range [IQR]=5–10). Three of the factors were medical comorbidities (asthma,[35] irritable bowel syndrome [IBS][39] and obesity[40]), and one was seropositivity for a typical perinatal pathogen (*T. gondii*[15]). The remaining three were childhood adversity,[36] head injury,[38] and exposure to obstetric complications.[37] Table 1 presents the risk factors, summary estimates and characteristics of those meta-analyses. The number of cases was >1000 in five (71.4%) meta-analyses. All meta-analyses were based on published data and none had access to individual participant data. The overall AMSTAR quality scores of the included meta-analyses were medium (median=7; IQR=4.5–8.5; Table S3).

Six (85.7%) of seven meta-analyses reported effects that were significant at a nominal *P* value of .05. Four (57.1%) were significant at *P* values <.001 under random effects modelling (Table 1): asthma,[35] childhood adversity,[36] IBS,[39] and obesity.[40] The 95% prediction interval rule under random-effects modelling did not include the null value only in the meta-analysis of IBS.[39] The meta-analysis that investigated the prevalence of BD in individuals with asthma[35] did not provide information with which to calculate prediction intervals.

The ES of the largest study was more conservative than the summary ES in the meta-analyses of childhood adversity,[36] IBS,[39] and obesity,[40] and in the meta-analysis of exposure to obstetric complications[37] the result was in the reverse direction. In two meta-analyses, the standard deviation (SD) of the largest study was <0.10. Two meta-analyses had large heterogeneity ($I^2 \geq 50\%$: childhood adversity[36] and *T. gondii* infection[15]) and one had very large heterogeneity ($I^2 \geq 75\%$: obesity[40]). The meta-analyses that assessed exposure to obstetric complications[37] and obesity[40] as risk factors for BD had evidence for small-study effects, which provides an indication of publication bias. The ES of the largest component study was not more conservative than the random-effects summary ES estimates for the meta-analyses of childhood adversity, IBS and obesity. In the meta-analysis of exposure to obstetric complications, the effect size of the largest study was in the reverse direction compared to the summary effect size calculated through random-effects modelling. Assuming that the effect size in the largest study represented the true effect of the meta-analysis, only the meta-analysis of obesity[40] showed a significant difference between the numbers of observed and expected 'positive' (i.e., statistically significant) studies providing evidence for excess of significance bias. The meta-analysis that investigated obesity included only cross-sectional studies.[40] The meta-analyses that investigated childhood adversity,[36] exposure to obstetric complications[37] or *T. gondii* infection[15] included only case–control studies. The meta-analyses that investigated asthma[35] and head injury[38] included cross-sectional and case–control studies. Only the meta-analysis that investigated IBS as a risk factor for BD included only retrospective cohort studies.[39]

The assessment of the seven meta-analyses is presented in Table 2. Only the meta-analysis of IBS[39] was nominally significant at a *P* level <10^{-6} per random-effects calculation and had no evidence of small-study effects, had no evidence for excess significance bias, did not have large heterogeneity, had a prediction interval that excluded the null and had >1000 cases. Therefore, IBS was classified as having class I evidence of being a risk factor for BD. The meta-analysis of childhood adversity[36] was significant at a *P* level <10^{-6} per random-effects calculation, had > 1000 cases, and had its largest component study with 95% CI excluding the null. Therefore, childhood adversity was classified as having class II evidence. The meta-analyses that evaluated asthma[35] and obesity[40] as possible environmental risk factors for BD met the criteria for class III evidence, and the meta-analyses of head injury[38] and *T. gondii* infection[15] met the criteria for weak evidence. Exposure to obstetric complications provided no evidence of association as a risk factor for BD.[37]

Three publications reported prevalence rates of BD.[34,41,42] The meta-analysis of Stubbs[34] included case–control and retrospective

TABLE 1 Characteristics, quantitative synthesis, and bias assessment of the seven meta-analyses of risk factors for bipolar disorder

	Risk factor	N of primary studies	Total number of cases/controls	Random effects summary effect size (95% CI)	95% PI	P random	P fixed	Largest study Effect size (95% CI)	SE	I^2	Egger's test P value
Wu et al.[35]	Asthma[a]	4	50 358/109 218	2.12 (1.57-2.87)	N/A	<.001	N/A	N/A	N/A	44	.514
Palmier-Claus et al.[36]	Childhood adversity[b]	13	1146/977	2.86 (2.03-4.04)	0.90-9.14	<.001	<.001	1.92 (1.39-2.64)	0.32	71	.567
Scott et al.[37]	Exposure to obstetric complications	8	272/341	1.15 (0.62-2.11)	0.23-5.81	.659	.799	0.58 (0.25-1.35)	0.28	49	.004
Perry et al.[38]	Head injury	3	313/5370	1.85 (1.17-2.94)	0.09-36.95	.009	.009	2.18 (1.22-3.91)	0.69	0	.201
Tseng et al.[39]	Irritable bowel syndrome (IBS)	6	177 117/192 092	2.48 (2.35-2.61)	2.30-2.66	<.001	<.001	2.47 (2.34-2.61)	0.07	0	.797
Zhao et al.[40]	Obesity	9	12 259/615 490	1.77 (1.40-2.23)	0.90-3.43	<.001	<.001	1.25 (1.19-1.30)	0.03	82	.019
Sutterland et al.[15]	*T. gondii* infection	11	1163/13 836	1.52 (1.05-2.19)	0.48-4.76	.025	<.001	2.11 (1.48-3.00)	0.39	67	.896

CI, confidence interval; N/A, not available; PI, prediction interval.
[a]Meta-analysis data were obtained as provided in the published report.
[b]Epidemiological studies were not included in the meta-analysis since they evaluated childhood adversity in a sample of bipolar patients.

TABLE 2 Assessment across the six meta-analyses of risk factors for bipolar disorder

	Sample size (number of cases)	Significance threshold reached (under the random-effects model)	95% prediction interval rule	Estimate of heterogeneity[a]	Small-study effects or excess significance bias	Random-effects summary effect size (95% CI)	Classification[b]
Asthma[35]	>1000	<0.001	N/A	Small	N/A	2.12 (1.57-2.87)	III
Childhood adversity[36]	>1000	<10^{-6}	Including the null value	Large	Neither	2.86 (2.03-4.04)	II
Exposure to obstetric complications[37]	<500	>0.05	Including the null value	Small	Small-study effects	1.15 (0.62-2.11)	Non-significant
Head injury[38]	<500	>0.001 but < 0.05	Including the null value	Small	Neither	1.85 (1.17-2.94)	Weak
Irritable bowel syndrome[39]	>1000	<10^{-6}	Excluding the null value	Small	Neither	2.48 (2.35-2.61)	I
Obesity[40]	>1000	>10^{-6} but <0.001	Including the null value	Very large	Both	1.77 (1.40-2.23)	III
T. gondii infection[15]	>1000	>0.001 but <0.05	Including the null value	Large	Neither	1.52 (1.05-2.19)	Weak

[a]Heterogeneity was categorized as not large (I^2<50%), large (I^2≥50% but I^2<75%), and very large (I^2≥75%).

[b]Convincing evidence criteria (class I): >1000 cases, significant summary associations ($P<10^{-6}$) per random-effects calculation, no evidence of small-study effects, no evidence of excess of significance bias, prediction intervals not including the null and heterogeneity not large (I^2<50%). Highly suggestive evidence criteria (class II): >1000 cases, significant summary associations ($P<10^{-6}$) per random-effects calculation, >1000 cases, and the largest study with 95% CI excluding the null. Suggestive evidence criteria (class III): >1000 cases and significant summary associations ($P<10^{-3}$) per random-effects calculation. Weak evidence criteria: all other risk factors with $P<.05$. Non-significant associations: all associations with $P>.05$.

cohort studies, and found that patients with fibromyalgia had a 15.2% prevalence rate of BD (95% CI=5.3%–36.3%; n=806 patients with fibromyalgia). The systematic review of cross-sectional studies conducted by Marrie et al.[42] reported that in patients with multiple sclerosis, lifetime prevalence of BD ranged from 0% to 16.2% (k=12 studies), and in the only study that was population based, the prevalence of BD was 5.8%. A systematic review reported a BD prevalence rate of 16.7% in patients with endometriosis when the three included studies were pooled together.[41] The overall AMSTAR scores of included meta-analyses were medium (median=6.5; IQR 3.75–7.75). Individual AMSTAR scores for included meta-analyses are provided in Table S3 (available online).

The qualitative systematic reviews found in seven publications evaluated a total of 37 unique risk factors with at least two individual studies. The median number of studies across these 37 systematic reviews was 3 (IQR 3–7). Of the seven publications, one included only case–control studies,[46] two included mixed cross-sectional and case–control studies,[14,41] one included mixed prospective cohorts and nested case–control studies[16] and the remaining three included mixed study designs (cross-sectional, cohort and case–control).[43-45] The overall AMSTAR quality scores of the qualitative systematic reviews were low (median=2; IQR=1.5–2.5; Table S3, available online). The factors were divided among socio-demographic factors (n=10), family-related factors (n=4), medical comorbidities (n=4), infections (n=8), pregnancy- and birth-related factors (n=5), individual factors (n=3), and medications/substance use (n=3). Table 3 presents each risk factor with the summary of the evidence. Five risk factors were investigated by a single study, with a median sample size of 26.5 participants (Table S4). For the socio-demographic factors, the largest body of evidence was provided for gender (k=14), and most studies found no significant association with BD.[43] Evidence for ethnicity[43] and place of residence[43] was conflicting, and most studies suggested either only a trend or no association with BD. For family-related factors, the largest body of evidence was provided for parental loss (k=10), but there were conflicting results (five studies suggested no association, three studies suggested an association and the remaining two provided inconclusive results, i.e., a non-significant trend).[43] Regarding medical comorbidities, the overall number of studies was low, with the inclusion of up to five studies. The studies reviewed across these qualitative systematic reviews are heterogeneous regarding classifications of exposures and do not provide directly comparable associations. For exposure to perinatal pathogens, the largest numbers of studies were found for cytomegalovirus (CMV) perinatal infection (k=11),[14] T. gondii perinatal infection (k=9)[14] and herpes simplex virus type 2 (HSV-2) perinatal infection (k=7).[14] For these three factors, the evidence was inconclusive or suggestive of no association with BD. For CMV perinatal infection[14] and T. gondii perinatal infection,[14] only approximately half the studies suggested an association. The influenza virus perinatal infection[14] was potentially associated with BD, as two out of three studies pointed to an association. Regarding pregnancy- and birth-related factors, birth seasonality[43] was the factor with the largest number of studies (k=9). Only small sample-sized studies suggested an association of winter–spring birth and increased risk for BD, whereas the largest studies

TABLE 3 Evidence across the systematic reviews of risk factors for bipolar disorder (BD)

Study	Environmental factor	N studies	Main findings
Sociodemographic factors			
Tsuchiya et al.[43]	Education	7	Two of seven studies supported an association between a higher educational level and an elevated risk for BD (n=2953). Three community surveys did not support this association (n=1513–4914). Two other community surveys suggested an inverse association (n=6673–18 572)
Tsuchiya et al.[43]	Education of parents	2	One of two studies found an association between a higher educational level of parents and an increased risk for BD (n=123). The other study found no association (n=1709; community adolescent sample)
Tsuchiya et al.[43]	Ethnicity	8	One study suggested an increased risk for BD in Caribbean-born subjects when compared with those born in the UK (n=2 million; registered sample, UK). Another study suggested a non-significant trend for non-white individuals being at higher risk for BD than white individuals (n=6673; community sample, USA]. One survey suggested higher rates of BD in Jews with a father of North African origin than in those with a father of European origin (n=4914; community sample, Israel). Three more community surveys in the USA did not support significant differences between Caucasians and other ethnic groups (n=1709–18 572), although it was found that Asians may be at lower risk only for DSM-defined bipolar I disorder than white individuals. One study showed an association between black ethnicity and a decreased risk for BD compared with white ethnicity (n=423 937; first-admitted subjects, USA). None of the various ethnicities in Ethiopia appeared to show an increased risk for BD (n=1420; community sample)
Tsuchiya et al.[43]	Gender	14	The community surveys have not shown a statistically significant gender difference in lifetime or period prevalence of BD (n=865–18 572). One study found a female predominance in an adolescent sample (age 14–18 years; n = 1710). Findings seem in favour of no association between a specific gender and an increased risk for BD, although the exceptions remain
Tsuchiya et al.[43]	Income	2	Two community surveys suggested a weak trend towards an association between lower income and an increased risk for BD
Tsuchiya et al.[43]	Marital status	7	Five of seven studies addressing marital status showed that single persons tended to have an elevated risk for BD compared with married or cohabiting persons. One of the remaining studies suggested that the association is limited to female subjects. The last study (community survey) showed no association
Tsuchiya et al.[43]	Occupation	3	One of three studies supported an association between a higher occupational class and an increased risk for BD (n=1500). Two of three studies did not support the association
Tsuchiya et al.[43]	Place of residence	8	Seven community surveys and register-based studies showed a trend for an association between urban residence and an increased risk for BD (n=7301–115 000). One survey suggested no association of place of residence and BD (n=3798)
Tsuchiya et al.[43]	Socio-economic status	3	Three studies exploring socio-economic status and BD that used a summary score showed inconsistent results. Two of them indicated an association between a higher social class and a slightly increased risk (n=123–938), whereas one indicated no association (n=2 million)
Tsuchiya et al.[43]	Unemployment	4	Two of four community surveys suggested a weak trend towards an association between unemployment and an increased risk for BD, while one suggested such an association was limited to male subjects. The last study implied no association
Family-related factors			
Tsuchiya et al.[43]	Child–parent relationship	4	Two of four studies found that a dysfunctional relationship with parents during childhood and adolescence was associated with an increased risk for BD. One study implied a similar association between a father's aggression and BD but not a mother's aggression, but the association disappeared after adjusting for subjects' psychiatric comorbidity. The fourth study did not support an association (n=19–5877)

(Continues)

TABLE 3 (Continued)

Study	Environmental factor	N studies	Main findings
Tsuchiya et al.[43]	Childbirth	3	Two of three studies suggested that giving birth is associated with an increased risk for BD in women within a 3-month period after the birth (n=36–50). The findings of another study supported this association in women within a 12-month postpartum period (n=1.2 million admitted female subjects followed up)
Tsuchiya et al.[43]	Parental occupation	3	Two of three studies suggested an association between higher occupational class of parents and an elevated risk for BD. One study did not support the association
Tsuchiya et al.[43]	Parental loss	10	Three of 10 studies found a statistically significant association between early parental loss (e.g., a death and/or a separation for a long period during childhood and adolescence) and an increased risk for BD (n=123–2.1 million births followed up). One study suggested a non-significant trend towards an association (n=79). One study indicated that only parental separation and not death had such an association, but the statistical significance disappeared after controlling for other social adversities and parental psychiatric disorders (n=5877). The rest of the studies did not support an association (n=19–462)
Medical comorbidities			
Vannucchi et al.[44]	Asperger syndrome	5	In adults with Asperger syndrome, BD comorbidity ranged from 6.0% to 21.4% of cases. Among patients with autism spectrum disorders (ASD), a positive family history for affective disorders was found in 17% and 13% of family members of autistic and Asperger subjects, respectively
Pope et al.[41]	Endometriosis	3	One of three studies found that women with pelvic pain related to endometriosis were more likely to have a BD diagnosis compared to women with chronic pelvic pain (n=39). Another study found no significant differences in the prevalence of BD between women with endometriosis and controls (n=67). The last study reported a prevalence of 62.7% for BD in women with endometriosis, with no control group for comparison (n=16)
Leo and Singh[45]	Migraine	5	Two clinic-based cross-sectional studies found that the weighted mean prevalence of BD in migraine patients diagnosed based on the IHS criteria was 9.0% (n=1102) (3.2-fold greater than the 12-month prevalence rates of BD in the general population). Two epidemiological studies in samples derived from the community found that the weighted mean prevalence of BD in patients diagnosed with the same criteria was 5.9% (2.1-fold greater than the 12-month prevalence rates of BD in the general population). The last study had a sample derived from a Health Maintenance Organization, and found a prevalence of 4.7% for type I BD and 3.9% for type II BD, and an OR=4.7 (1.4–15.4) comparing migraine vs non-migraine patients
Cirillo et al.[46]	Premenstrual syndrome or premenstrual dysphoric disorder	3	One study in a community sample found that, among 201 subjects with subthreshold PMDD, 3.8% had BD-I (OR=5.3) and 0.3% had BD-II (OR 0.5). In another study among 74 patients with PMDD, 5.7% had BD-I (OR=7.9) and 4.9% had BD-II (OR=8.1), while 0.8% of subjects without PMDD (n=828) had BD-I and 0.6% had BD-II. Another study found a prevalence of BD of 9.0% in controls, 17% in depressed women in the peri-menstrual (peri-MS) period, and 15% in non-depressed women in the peri-MS period (n=247); this study assessed seven psychological symptoms for the peri-MS period. The final study found that women with late luteal phase dysphoric disorder scored higher on measures of hypomania than controls at all menstrual cycle phases (elevated, unstable moods, impulsiveness, overreactivity and irritability) (n=30)
Infections			
Barichello et al.[14]	BoDV perinatal infection	2	One of two studies demonstrated an association between BoDV and BD; in bipolar patients, BoDV circulating immune complexes were significantly elevated (45.3%; P=.001). However, Hornig and colleagues performed a case–control study utilizing molecular assays (RT-PCR and PCR) and serological assays (ELISA and Immunofluorescence Assay [IFA]) to evaluate the presence of BoDV virus or antibodies. The authors did not find immunoreactivity to He/80, Strain V, No/98, Universal, or Avian BoDV genotypes 1–4 in samples from bipolar patients

TABLE 3 (Continued)

Study	Environmental factor	N studies	Main findings
Barichello et al.[14]	CMV perinatal infection	11	Five of 11 studies showed significant associations between CMV antibody levels and BD. In one study, CMV IgG concentrations were higher in BD compared to healthy controls. Another study showed that when groups of seropositive and seronegative BD patients were compared, there was a decrease in the right hippocampal volume in CMV-positive patients (P=.044)
Barichello et al.[14]	HSV-1 perinatal infection	5	Two of five studies showed an association between HSV-1 and BD
Barichello et al.[14]	HSV-2 perinatal infection	7	One of seven studies showed an association between HSV-2 and BD
Barichello et al.[14]	HHV-6 perinatal infection	2	No study demonstrated an association between HHV-6 and BD
Barichello et al.[14]	Influenza virus perinatal infection	3	Two of three studies demonstrated an association between influenza infection and BD
Tsuchiya et al.[43]	Influenza virus prenatal infection	5	One study implied a trend towards statistical significance for an increased risk of an occurrence of BD from exposure during the second trimester (n=681 births followed up). The other studies did not support this trend (n=525–2.1 million births followed up)
Barichello et al.[14]	*Toxoplasma gondii* perinatal infection	9	Five of nine studies showed an association of perinatal *T. gondii* infection and BD
Pregnancy- and birth-related factors			
Tsuchiya et al.[43]	Birth seasonality	9	Six of the nine studies supported an association between a winter–spring birth and an elevated risk for BD, compared with general live-birth statistics (n=294–18 021). Three other studies did not support this association (n=220–2.1 million births followed up)
Marangoni et al.[16]	Indicators of fetal development (gestational age, birth weight and Apgar score)	3	One study found that pre-term birth (<37 weeks) alone, or associated with low birth weight (<2500 g), increased the risk of BD only in female individuals. A second study found a seven-fold increase in the risk of BD in very pre-term individuals (<32 weeks), and a three-fold increased risk in pre-term individuals (32–36 weeks) of both sexes. The third study found that only planned delivery by caesarean section increased the risk of BD among several factors (Apgar score, birth presentation, birth type, uterine bleeding and induced labour)
Marangoni et al.[16]	Physical and emotional stress during pregnancy (famine and war stress)	3	Prenatal exposure to war during the first trimester increased the risk for BD (one study). Prenatal famine (one study) and maternal bereavement (one study) were not associated with BD
Tsuchiya et al.[43]	Pregnancy and/or birth complications (PBCs)	7	Three of seven studies suggested an association between a higher score and an elevated risk for BD (n=110; measured using an early version of Lewis's score; n=16–30; measured using Mirdal's score). The other studies did not support this. Results regarding summary scores of PBCs are conflicting. The inconsistency may result from the varying definitions of PBCs used
Marangoni et al.[16]	Smoking during pregnancy	2	In the Northern California Birth Cohort, a 2-fold increased risk of BD in offspring of mother who smoked during pregnancy was detected. In an independent sample this association was not replicated
Individual factors			
Tsuchiya et al.[43]	Handedness	2	BD was not associated with handedness (n=36–88)
Tsuchiya et al.[43]	Premorbid adjustment	3	One of three studies indicated that premorbid adjustment [as measured by means of the Premorbid Adjustment Scale] of subjects with BD was poorer than that of normal controls during adolescence, but this was not so during childhood (n=28). Another study suggested a similar association by means of the Global Assessment of Functioning score (n=1709). The third study suggested that disciplinary difficulties at school predict BD (n=462)
Tsuchiya et al.[43]	Recent stressful events	4	Three of four studies suggested that an exposure to recent stressful events occurring within a short period prior to the first onset (e.g., within 6 months) was associated with an increased risk for BD (n=31–50). This was not supported by another study (n=14)

(Continues)

TABLE 3 (Continued)

Study	Environmental factor	N studies	Main findings
Medications/substance use			
Marangoni et al.[16]	Cannabis	3	Three community studies suggested an association with BD. The studies reported an aOR=1.03–4.98
Marangoni et al.[16]	Opioids	2	Two community studies suggested an association of opioid use and BD. The first study reported an aOR of 2.0 (1.1–3.7) (95% CI), with 1499 exposed and 33 154 non-exposed. The second study reported an aOR of 2.12 (1.52–2.96) for weekly/daily use, with 461 exposed and 17 011 non-exposed
Marangoni et al.[16]	Tranquilizers/sedatives	2	One community study in subjects with lifetime alcohol abuse, substance abuse, MDD or anxiety disorder found an association of the use of tranquilizers/sedatives with BD (aOR=1.50 [1.15–1.94]; 3 years follow-up; n=15 329). Another community study found a non-significant association with the use of sedatives/tranquilizers and BD (n=17 405)

aOR, adjusted odds ratio; BoDV, Borna disease virus; PBCs, pregnancy and/or birth complications; CMV, cytomegalovirus; EBV, Epstein–Barr virus; ELISA, enzyme-linked immunosorbent assay; HHV-6, human herpes virus-6; HSV, herpes simplex virus; IgG, immunoglobulin G; IHS, International Headache Society; IQ, Intelligence Quotient; MDD, major depressive disorder; OR, odds ratio; PMDD, premenstrual dysphoric disorder; RT-PCR, reverse transcription–polymerase chain reaction; VZV, varicella-zoster virus.

suggested no association. For the seven studies assessing pregnancy and birth complications (PBCs),[43] evidence was inconclusive, with different methods of assessment of PBCs. One nested case–control study suggested that pre-term birth (<37 weeks) may increase the risk of BD in female individuals,[47] while a cohort study provided evidence that pre-term birth (32–36 weeks) increased by 3-fold the risk of BD in both genders.[48] For the individual factors, three of four studies (n=31–50) showed that exposure to recent stressful events occurring within a short period prior to the first onset (e.g. within 6 months)[43] was associated with an increased risk for BD. Finally, reviewed studies on medications and substance use suggested an association of cannabis[16] or opioid use[16] with BD (k=2–3). Meta-analyses were not performed due to high heterogeneity.[16]

4 | DISCUSSION

We provide a systematic assessment of putative environmental risk factors for BD across published systematic reviews and meta-analyses by applying predefined methodological criteria. To the best of our knowledge, this represents the first effort to synthesize available evidence considering potential biases in this literature. Compared to previous similar efforts in a range of neuropsychiatric disorders,[18,19,30] our data indicate that the search for environmental risk factors for BD has been thus far a relatively under-studied area of investigation. One of the most relevant roles of umbrella reviews and other systematic approaches to integrate evidence is to identify areas where further research efforts should be directed.[49]

We identified seven meta-analyses that investigated associations of environmental risk factors with BD. Irritable bowel syndrome was the only risk factor for BD that met criteria for class I evidence, and exposure to childhood adversity met criteria for class II evidence. Obesity and asthma were risk factors that met criteria for class III evidence, while a history of head injury and seropositivity

to *T. gondii* were supported by weak evidence. Bipolar disorder is associated with high rates of co-morbid medical conditions which at least in part may be due to shared environmental risk factors and pathophysiological pathways, and these co-occurring medical conditions may make a significant contribution to the decreased life expectancy observed among individuals with BD.[3,50,51] For example, an increase in peripheral inflammation observed in individuals with IBS[52] may contribute to neuroinflammation, which is thought to be a relevant pathophysiological event in BD.[53,54] Furthermore, stressful life events may precipitate the onset of both BD (as observed in the systematic review conducted by Tsuchiya et al.[43]) and IBS.[55] Likewise, several mechanistic pathways including but not limited to immune dysfunction and genetic polymorphisms and abnormalities in the circadian system may contribute to a higher prevalence of BD in obese individuals.[56,57] Although we found that only weak evidence supports asthma as a putative risk factor for BD, a recent large prospective study found that asthma and other atopic diseases may increase the risk of BD.[58]

A history of traumatic brain injury was associated with BD in a meta-analysis that included three studies, which had either cross-sectional or case–control designs.[38] However, this recent meta-analysis did not include at least two large-scale prospective studies that found evidence that traumatic brain injury may increase the risk of BD.[59,60] Therefore, clearly the incorporation of these and future studies may require an updated synthesis of available evidence in the near future.

Accumulating evidence provides increasing support for the notion that neurodevelopmental factors may play a role in the patho-aetiology of BD.[13,61] Seropositivity to *T. gondii* may confer a higher risk for BD, although the epidemiological credibility of the available evidence is weak, while a recent systematic review suggests that perinatal influenza infection may increase the risk of BD.[14] Exposure to perinatal pathogens may activate immune mechanisms, leading to a long-term up-regulation of immune systems, and since immune factors influence neural growth and survival, this may disrupt

neurodevelopmental trajectories.[62,63] A recent study found evidence for a gene–environmental interaction involving the rs3804099 single nucleotide polymorphism (SNP) of the toll-like receptor 2 (*TLR2*) gene in BD.[64] This study provides preliminary evidence in support of the hypothesis that prenatal immune activation due to exposure to pathogens may modulate immune pathways relevant to the pathophysiology of BD. The role of neurodevelopmental factors in BD is further supported by the finding that pre-term birth may be a risk factor for BD, although this evidence was supported only by a qualitative systematic review.[16]

Qualitative systematic reviews provide some suggestive clues to several possible environmental risk factors for BD. For example, preliminary evidence indicates that the use of cannabis and opioids may confer a higher risk for BD.[16] In addition, proximal stressful life events (i.e., those occurring up to 6 months prior to illness onset) may increase the risk of BD.[43]

Some limitations of this umbrella review deserve discussion. First, the assessment of heterogeneity and excess of significance findings provides hints of bias but not proof thereof. Several sources of true heterogeneity are possible. For example, BD is per se a heterogeneous phenotype with highly variable illness trajectories.[65,66] In addition, the multivariable adjustment of potential confounders (e.g., co-occurring metabolic disturbances)[67] could vary across component studies included in eligible meta-analyses, thus providing a possible source of heterogeneity. Second, we did not assess the quality of individual studies included in the systematic reviews and meta-analyses because this was beyond the scope of this umbrella review. This was a primary aim of the systematic reviews and meta-analyses included herein. Third, we collected only putative environmental risk factors which have been evaluated through systematic reviews and meta-analyses. Thus, we might have missed some associations which had not yet been evaluated in systematic reviews and meta-analyses. For example, an unhealthier dietary pattern, exposure to smoking in utero, and exposure to corticosteroids may be putative risk factors for BD which deserve further scrutiny. Fourth, the methodological quality of included meta-analyses was in general medium, whereas the methodological quality of narrative systematic reviews was overall low. Finally, we found no protective environmental factor for BD supported by robust evidence.

Despite these limitations, this umbrella review has important relevant clinical and research implications. First and foremost, BD is a heterogeneous phenotype and several of the environmental risk factors evaluated in this effort seem to cross traditional diagnostic categories. For example, evidence indicates that IBS may be a risk factor for major depressive disorder,[68] while exposure to perinatal pathogens could be a non-specific risk factor for several disorders with a neurodevelopmental component (e.g., schizophrenia and autism).[62] Some risk factors may increase the risk of certain subtypes of BD. For example, an increasing body of evidence indicates that early-onset BD may have some specific pathophysiological mechanisms.[69,70] Finally, this umbrella review indicates that the fine mapping of putative environmental risk factors for BD deserves further study.

5 | CONCLUSIONS

This umbrella review of systematic reviews and meta-analyses identified 51 unique risk factors for BD. However, only IBS emerged as a risk factor supported by class I evidence. In addition, relatively few putative environmental risk factors for BD have been evaluated through meta-analyses, and several hints of bias were found in this literature. Recently, efforts have been directed to characterizing precursors or even a prodrome of BD. The identification of environmental risk factors for BD requires further study, and may further aid in the characterization of individuals at risk to develop BD, who ultimately may benefit from preventative interventions.

DISCLOSURE

The authors declare no conflicts of interest relevant to the current work.

REFERENCES

1. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. *Arch Gen Psychiatry*. 2011;68:241-251.
2. Kessing LV, Vradi E, Andersen PK. Life expectancy in bipolar disorder. *Bipolar Disord*. 2015;17:543-548.
3. Kessing LV, Vradi E, McIntyre RS, Andersen PK. Causes of decreased life expectancy over the life span in bipolar disorder. *J Affect Disord*. 2015;180:142-147.
4. Vancampfort D, Vansteelandt K, Correll CU, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. *Am J Psychiatry*. 2013;170: 265-274.
5. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. *Lancet (London, England)*. 2016;387:1561-1572.
6. Song J, Bergen SE, Kuja-Halkola R, Larsson H, Landen M, Lichtenstein P. Bipolar disorder and its relation to major psychiatric disorders: a family-based study in the Swedish population. *Bipolar Disord*. 2015;17:184-193.
7. Bienvenu OJ, Davydow DS, Kendler KS. Psychiatric 'diseases' versus behavioral disorders and degree of genetic influence. *Psychol Med*. 2011;41:33-40.
8. Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating missing heritability for disease from genome-wide association studies. *Am J Hum Genet*. 2011;88:294-305.
9. Post RM. Epigenetic basis of sensitization to stress, affective episodes, and stimulants: implications for illness progression and prevention. *Bipolar Disord*. 2016;18:315-324.
10. Uher R. Gene-environment interactions in severe mental illness. *Front Psychiatry*. 2014;5:48.

11. Sanches M, Keshavan MS, Brambilla P, Soares JC. Neurodevelopmental basis of bipolar disorder: a critical appraisal. *Prog Neuropsychopharmacol Biol Psychiatry*. 2008;32:1617-1627.

12. Bora E. Developmental trajectory of cognitive impairment in bipolar disorder: comparison with schizophrenia. *Eur Neuropsychopharmacol*. 2015;25:158-168.

13. Madison JM, Zhou F, Nigam A, et al. Characterization of bipolar disorder patient-specific induced pluripotent stem cells from a family reveals neurodevelopmental and mRNA expression abnormalities. *Mol Psychiatry*. 2015;20:703-717.

14. Barichello T, Badawy M, Pitcher MR, et al. Exposure to Perinatal Infections and Bipolar Disorder: a Systematic Review. *Curr Mol Med*. 2016;16:106-118.

15. Sutterland AL, Fond G, Kuin A, et al. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. *Acta Psychiatr Scand*. 2015;132:161-179.

16. Marangoni C, Hernandez M, Faedda GL. The role of environmental exposures as risk factors for bipolar disorder: a systematic review of longitudinal studies. *J Affect Disord*. 2016;193:165-174.

17. Agnew-Blais J, Danese A. Childhood maltreatment and unfavourable clinical outcomes in bipolar disorder: a systematic review and meta-analysis. *Lancet Psychiatry*. 2016;3:342-349.

18. Bellou V, Belbasis L, Tzoulaki I, Evangelou E, Ioannidis JP. Environmental risk factors and Parkinson's disease: an umbrella review of meta-analyses. *Parkinsonism Relat Disord*. 2016;23:1-9.

19. Bellou V, Belbasis L, Tzoulaki I, Middleton LT, Ioannidis JP, Evangelou E. Systematic evaluation of the associations between environmental risk factors and dementia: an umbrella review of systematic reviews and meta-analyses. *Alzheimers Dement*. 2017;13:406-418.

20. Carvalho AF, Kohler CA, Fernandes BS, et al. Bias in emerging biomarkers for bipolar disorder. *Psychol Med*. 2016;46:2287-2297.

21. Bakkalbasi N, Bauer K, Glover J, Wang L. Three options for citation tracking: google Scholar, Scopus and Web of Science. *Biomed Digit Libr*. 2006;3:7.

22. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. *Ann Intern Med*. 1997;127:820-826.

23. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. *J R Stat Soc Ser A (Stat Soc)*. 2009;172: 137-159.

24. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002;21:1539-1558.

25. Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. *BMJ (Clinical research ed)*. 2007;335:914-916.

26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ (Clinical research ed)*. 1997;315:629-634.

27. Carvalho AF, Köhler CA, Brunoni AR, et al. Bias in Peripheral Depression Biomarkers. *Psychother Psychosom*. 2016;85:81-90.

28. Ioannidis JP, Trikalinos TA. An exploratory test for an excess of significant findings. *Clinical trials (London, England)*. 2007;4:245-253.

29. Ioannidis JP. Clarifications on the application and interpretation of the test for excess significance and its extensions. *J Math Psychol*. 2013;57:184-187.

30. Belbasis L, Bellou V, Evangelou E, Ioannidis JP, Tzoulaki I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. *Lancet Neurol*. 2015;14: 263-273.

31. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Med Res Methodol*. 2007;7:10.

32. Shea BJ, Hamel C, Wells GA, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. *J Clin Epidemiol*. 2009;62:1013-1020.

33. Kudlow PA, Rosenblat JD, Weissman CR, et al. Prevalence of fibromyalgia and co-morbid bipolar disorder: a systematic review and meta-analysis. *J Affect Disord*. 2015;188:134-142.

34. Stubbs B. A random effects meta-analysis investigating the prevalence of bipolar disorder in people with fibromyalgia: an updated analysis. *J Affect Disord*. 2016;191:308-309.

35. Wu MK, Wang HY, Chen YW, Lin PY, Wu CK, Tseng PT. Significantly Higher Prevalence Rate of Asthma and Bipolar Disorder Co-Morbidity: a Meta-Analysis and Review Under PRISMA Guidelines. *Medicine*. 2016;95:e3217.

36. Palmier-Claus JE, Berry K, Bucci S, Mansell W, Varese F. Relationship between childhood adversity and bipolar affective disorder: systematic review and meta-analysis. *Br J Psychiatry*. 2016;209:454-459.

37. Scott J, McNeill Y, Cavanagh J, Cannon M, Murray R. Exposure to obstetric complications and subsequent development of bipolar disorder: systematic review. *Br J Psychiatry*. 2006;189:3-11.

38. Perry DC, Sturm VE, Peterson MJ, et al. Association of traumatic brain injury with subsequent neurological and psychiatric disease: a meta-analysis. *J Neurosurg*. 2016;124:511-526.

39. Tseng PT, Zeng BS, Chen YW, Wu MK, Wu CK, Lin PY. A meta-analysis and systematic review of the comorbidity between irritable bowel syndrome and bipolar disorder. *Medicine*. 2016;95:e4617.

40. Zhao Z, Okusaga OO, Quevedo J, Soares JC, Teixeira AL. The potential association between obesity and bipolar disorder: a meta-analysis. *J Affect Disord*. 2016;202:120-123.

41. Pope CJ, Sharma V, Sharma S, Mazmanian D. A Systematic review of the association between psychiatric disturbances and endometriosis. *J Obst Gynaecol Can*. 2015;37:1006-1015.

42. Marrie RA, Reingold S, Cohen J, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. *Multiple sclerosis*. 2015;21:305-317.

43. Tsuchiya KJ, Byrne M, Mortensen PB. Risk factors in relation to an emergence of bipolar disorder: a systematic review. *Bipolar Disord*. 2003;5:231-242.

44. Vannucchi G, Masi G, Toni C. Dell'Osso L, Erfurth A, Perugi G. Bipolar disorder in adults with Aspergers Syndrome: a systematic review. *J Affect Disord*. 2014;168:151-160.

45. Leo RJ, Singh J. Migraine headache and bipolar disorder comorbidity: a systematic review of the literature and clinical implications. *Scand J Pain*. 2016;11:136-145.

46. Cirillo PC, Passos RB, Bevilaqua MC, Lopez JR, Nardi AE. Bipolar disorder and Premenstrual Syndrome or Premenstrual Dysphoric Disorder comorbidity: a systematic review. *Revista brasileira de psiquiatria (Sao Paulo. Brazil. 1999)*. 2012;467-479.

47. Ogendahl BK, Agerbo E, Byrne M, Licht RW, Eaton WW, Mortensen PB. Indicators of fetal growth and bipolar disorder: a Danish national register-based study. *Psychol Med*. 2006;36:1219-1224.

48. Nosarti C, Reichenberg A, Murray RM, et al. Preterm birth and psychiatric disorders in young adult life. *Arch Gen Psychiatry*. 2012;69:E1-E8.

49. Egger M, Smith GD, O'rourke K. Rationale, potentials, and promise of systematic reviews. In: Egger M, Smith GD, Altman DG, eds. *Systematic Reviews in Health Care: meta-Analysis in Context*. 2nd ed. London: BMJ Publishing Group; 2001:1-19.

50. Liu CS, Carvalho AF, Mansur RB, McIntyre RS. Obesity and bipolar disorder: synergistic neurotoxic effects? *Adv Ther*. 2013;30:987-1006.

51. Vancampfort D, Mitchell AJ, De Hert M, et al. Prevalence and predictors of type 2 diabetes mellitus in people with bipolar disorder: a systematic review and meta-analysis. *J Clin Psychiatry*. 2015;76:1490-1499.

52. O'Malley D, Quigley EM, Dinan TG, Cryan JF. Do interactions between stress and immune responses lead to symptom exacerbations in irritable bowel syndrome? *Brain Behav Immun*. 2011;25:1333-1341.

53. Jakobsson J, Bjerke M, Sahebi S, et al. Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. *J Psychiatry Neurosci*. 2015;40:250-258.

54. Leboyer M, Soreca I, Scott J, et al. Can bipolar disorder be viewed as a multi-system inflammatory disease? *J Affect Disord*. 2012;141:1-10.

55. Hungin AP, Becher A, Cayley B, et al. Irritable bowel syndrome: an integrated explanatory model for clinical practice. *Neurogastroenterol Motil*. 2015;27:750-763.

56. Valenzuela FJ, Vera J, Venegas C, et al. Evidences of polymorphism associated with circadian system and risk of pathologies: a review of the literature. *Int J Endocrinol*. 2016;2016:2746909.

57. Rosenblat JD, McIntyre RS. Are medical comorbid conditions of bipolar disorder due to immune dysfunction? *Acta Psychiatr Scand*. 2015;132:180-191.

58. Wei HT, Lan WH, Hsu JW, et al. Risk of developing major depression and bipolar disorder among adolescents with atopic diseases: a nationwide longitudinal study in Taiwan. *J Affect Disord*. 2016;203:221-226.

59. Orlovska S, Pedersen MS, Benros ME, Mortensen PB, Agerbo E, Nordentoft M. Head injury as risk factor for psychiatric disorders: a nationwide register-based follow-up study of 113 906 persons with head injury. *Am J Psychiatry*. 2014;171:463-469.

60. Chi YC, Wu HL, Chu CP, Huang MC, Lee PC, Chen YY. Traumatic brain injury and affective disorder: a nationwide cohort study in Taiwan, 2000-2010. *J Affect Disord*. 2016;191:56-61.

61. Arango C, Fraguas D, Parellada M. Differential neurodevelopmental trajectories in patients with early-onset bipolar and schizophrenia disorders. *Schizophr Bull*. 2014;40(Suppl 2):S138-S146.

62. Harvey L, Boksa P. Prenatal and postnatal animal models of immune activation: relevance to a range of neurodevelopmental disorders. *Dev Neurobiol*. 2012;72:1335-1348.

63. Meyer U, Feldon J, Schedlowski M, Yee BK. Immunological stress at the maternal-foetal interface: a link between neurodevelopment and adult psychopathology. *Brain Behav Immun*. 2006;20:378-388.

64. Oliveira J, Kazma R, Le Floch E, et al. Toxoplasma gondii exposure may modulate the influence of TLR2 genetic variation on bipolar disorder: a gene-environment interaction study. *Int J Bipolar Disord*. 2016;4:11.

65. Miskowiak KW, Kjaerstad HL, Meluken I, et al. The search for neuroimaging and cognitive endophenotypes: A critical systematic review of studies involving unaffected first-degree relatives of individuals with bipolar disorder. *Neurosci Biobehav Rev*. 2017;73:1-22.

66. Birmaher B, Gill MK, Axelson DA, et al. Longitudinal trajectories and associated baseline predictors in youths with bipolar spectrum disorders. *Am J Psychiatry*. 2014;171:990-999.

67. Mansur RB, Brietzke E, McIntyre RS. Is there a "metabolic-mood syndrome"? A review of the relationship between obesity and mood disorders. *Neurosci Biobehav Rev*. 2015;52:89-104.

68. Lee YT, Hu LY, Shen CC, et al. Risk of Psychiatric Disorders following Irritable Bowel Syndrome: a Nationwide Population-Based Cohort Study. *PLoS ONE*. 2015;10:e0133283.

69. Geoffroy PA, Etain B, Jamain S, Bellivier F, Leboyer M. Early onset bipolar disorder: validation from admixture analyses and biomarkers. *Can J Psychiatry*. 2013;58:240-248.

70. Nassan M, Li Q, Croarkin PE, et al. A genome wide association study suggests the association of muskelin with early onset bipolar disorder: implications for a GABAergic epileptogenic neurogenesis model. *J Affect Disord*. 2016;208:120-129.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.